Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Inozyme Pharma, Inc. | inzy-ex321_7.htm |
| EX-31.2 - EX-31.2 - Inozyme Pharma, Inc. | inzy-ex312_8.htm |
| EX-31.1 - EX-31.1 - Inozyme Pharma, Inc. | inzy-ex311_6.htm |
| EX-23.1 - EX-23.1 - Inozyme Pharma, Inc. | inzy-ex231_646.htm |
| EX-21.1 - EX-21.1 - Inozyme Pharma, Inc. | inzy-ex211_355.htm |
| EX-10.21 - EX-10.21 - Inozyme Pharma, Inc. | inzy-ex1021_356.htm |
| EX-10.20 - EX-10.20 - Inozyme Pharma, Inc. | inzy-ex1020_1008.htm |
| EX-10.16 - EX-10.16 - Inozyme Pharma, Inc. | inzy-ex1016_1007.htm |
| EX-4.2 - EX-4.2 - Inozyme Pharma, Inc. | inzy-ex42_239.htm |
| 10-K - 10-K - Inozyme Pharma, Inc. | inzy-10k_20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Inozyme Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 25, 2021 |
|
By: |
/s/ Stephen Basso |
|
|
|
|
Stephen Basso |
|
|
|
|
Senior Vice President, Finance (Principal Financial Officer and Principal Accounting Officer) |